Apr. 26 at 3:07 AM
$GANX
If anyone thinks the phase II trial Gain sponsors, whether alone or with a partner, will go full term you are short sighted. The moral, and ethical, implications of watching patients on the drug dramatically improving while those on placebo continuing a downward spiral will force the trial to end early. I predict, and just my guess, at 180 days the trial ends and those on placebo rollover to 2287.
No clinician, caretaker, or regulator at the FDA will allow patients to be intentionally harmed due to a clinical trial for such a pervasive disease with no real treatment options.
Why do I know this? Lets just say in my line of work, I know first hand the devastation that occurs with this disease. If Gain enrolls a full patient population for a phase II, treats it like a phase III, and we see similiar results to the phase I B results, the story ends at 180 days, maybe 210 - at the longest.
